BMC Cancer, 2023 Background Due to the high drug resistance of hepatocellular carcinoma (HCC), sorafenib has limited efficacy in the treatment of advanced HCC. Cancer-associated fibroblasts (CAFs) play an important regulatory role in the induction of chemoresistance ...
Jiali Zhao +12 more
doaj +1 more source
Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53 independent pathways [PDF]
, 2014 Most cancer cells use aerobic glycolysis to fuel their growth. The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer’s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD þ ) from reduced nicotinamide adenine
Allison, Simon J. +6 more
core +1 more source
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. [PDF]
, 2014 Hypertension after treatment with vascular endothelial growth factor (VEGF) receptor inhibitors is associated with superior treatment outcomes for advanced cancer patients.
Bakris, GL +13 more
core +2 more sources
Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies [PDF]
, 2019 A significantly increased level of the reactive oxygen species (ROS) scavenger glutathione (GSH) has been identified as a hallmark of renal cell carcinoma (RCC). The proposed mechanism for increased GSH levels is to counteract damaging ROS to sustain the
Meierhofer, David, Xiao, Yi
core +2 more sources
Neoplasia: An International Journal for Oncology Research, 2014 Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a small multikinase inhibitor, is the only approved therapy for advanced HCC.
Jung-Chen Su +9 more
doaj +1 more source
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer [PDF]
, 2016 Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer ...
A Hayashi +130 more
core +1 more source
Cell Death and Disease, 2023 Sorafenib, a first-line drug for advanced hepatocellular carcinoma (HCC), shows a favorable anti-tumor effect while resistance is a barrier impeding patients from benefiting from it. Thus, more efforts are needed to lift this restriction.
Feng-li Xu +8 more
doaj +1 more source
Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines. [PDF]
PLoS ONE, 2017 BACKGROUND:Despite recent advances in treatment strategies, it is still difficult to cure patients with hepatocellular carcinoma (HCC). Sorafenib is the only approved multiple kinase inhibitor for systemic chemotherapy in patients with advanced HCC.
Yuki Haga +7 more
doaj +1 more source
Mechanism of sorafenib resistance associated with ferroptosis in HCC
Frontiers in Pharmacology, 2023 Hepatocellular carcinoma (HCC) is the most familiar primary hepatic malignancy with a poor prognosis. The incidence of HCC and the associated deaths have risen in recent decades.
Lingling Guo +3 more
doaj +1 more source
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma [PDF]
, 2018 Background: This multicentre, open-label, phase-I/randomised phase-II trial evaluated safety, pharmacokinetics, maximum-tolerated-dose (MTD) per dose-limiting toxicities (DLTs), and efficacy of nintedanib vs.
Deptala, A +11 more
core +3 more sources